Cancer & Oncology treatment

“The right treatment for the right patient at the right time and at the right place.” …is the motto of the National Cancer Control Programme.

There is a network of 13 main specialized centers for the cancer treatment, every of them with several regional „satellites“ covering the whole country which guarantee a good access to oncology care for all patients. The most complex and expensive care in the field of diagnostics and treatment of tumor illnesses has been transferred from the network of hospitals to these sites. Pharmnet is continuously present with its projects at these sites. Click here to learn more about our experience in oncology clinical trials.

The National Cancer Control Programme was created in accordance with the conditions and needs of the Czech Republic and in compliance with the conclusions of WHO Consultation on Strategies to Improve and Strengthen Cancer Control Programmes in Europe. The general aids are reduction of cancer incidence and mortality, improvement in the quality of life of cancer patients, enhancement of effectiveness of cancer diagnosis and therapy in the Czech republic. One of the main points of the programme are prevention and screening programmes.. National treatment guidelines are based on international guidelines of NCCN (National Comprehensive Cancer Network, Inc.), ASCO (The American Society of Clinical Oncology), ESMO ( The European Society for Medical Oncology), Czech Society for Oncology.

In the Czech Republic more than 73 000 tumour diseases are newly diagnosed every year. Malignant neoplasms cause one quarter of all deaths in the Czech Republic, being the second most frequent cause of death after cardiovascular diseases. The most frequent neoplasms is “other MN of skin” with the share 24 % and with low fatality. The highest mortality from MN is for lung cancer in men with 76.7 deaths per 100 000 men and in women for breast cancer with 31.2 deaths per 100 000 women.

Epidemiology of malignit tumours in Czech Republic is publicly available and can be found on interactive website www.svod.cz (available also in English). National registry of oncology diseases contains over 1,5 mil. of cases; each case contains 30 characteristics. We can prepare a summary of these statistics upon request.

The Czech Republic achieved significant improvements internationally in reducing mortality from breast cancer. Greater emphasis on screening for breast cancer has significantly contributed to the reduction of mortality in this disease in the last decade from 25,6 to 18,6 (per 100,000 women). This led to one of the best rankings in OECD countries. Despite the introduction of new screening programme for colon cancer and decline in the mortality rate, the Czech Republic still holds one of the leading positions in mortality for this disease.

2.1.1 Notified cases of malignant neoplasms (year 2009) - males


Notified cases of malignant neoplasms (year 2009) - males

2.1.2 Notified cases of malignant neoplasms (year 2009) - females


notified_cases_of_malignant_neoplasms-females_part1

2.1.2 Notified cases of malignant neoplasms (year 2009) - females


notified_cases_of_malignant_neoplasms-females_part2

Verbal indication of diagnoses (ICD-10) used in Tables  2.1

Verbal indication of diagnoses (ICD-10)

Source: Czech Health Statistics Yearbook, 2011, Institute of Health Information and Statistics of the Czech Republic

5.4 Structure of distributed drugs main groups


Structure of distributed drugs main groups

5.10.1. Colorectal cancer, five-year relative survival rate, 1997-2002 and 2004-09 (or nearest period)


Colorectal cancer, five-year relative survival rate

5.10.2. Colorectal cancer, five-year relative survival rate by sex, 2004-09 (or nearest period)


Colorectal cancer, five-year relative survival rate by sex

5.10.3. Colorectal cancer mortality 2000 to 2009 (or nearest period)


Colorectal cancer mortality 2000 to 2009 (or nearest period)

Source: OECD (2011), Health at a Glance 2011: OECD Indicators, OECD Publishing.
http://dx.dor.org/10.1787/health_glance-2011-en

ISO Across Alliance
We are going to California!Meet us in September at Outsourcing in Clinical Trials.http://www.arena-international.com/octsocal 
LinkedIn
Pharmnet © 2017